Trials / Sponsors / Autolus Limited
Autolus Limited
Industry · 11 registered clinical trials — 5 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis Lupus Nephritis | Phase 2 | 2025-09-01 |
| Recruiting | Obe-cel in Refractory Progressive Forms of Multiple Sclerosis Progressive Multiple Sclerosis | Phase 1 | 2025-08-04 |
| Recruiting | Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus Systemic Lupus Erythematosus | Phase 1 | 2024-02-02 |
| Recruiting | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lym Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Phase 1 | 2023-11-16 |
| Active Not Recruiting | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphob Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2020-06-03 |
| Terminated | Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymph T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | 2018-08-30 |
| Enrolling By Invitation | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL | Phase 2 | 2018-08-02 |
| Terminated | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cel Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | 2017-09-05 |
| Completed | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2017-06-26 |
| Terminated | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2017-05-05 |
| Available | Expanded Access Program for OOS Obe-cel Lymphoblastic Leukemia, Acute, Adult, B Cell ALL | — | — |